Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rhenium (186Re) obisbemeda by Plus Therapeutics for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis): Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Leptomeningeal Disease (Neoplastic Meningitis,...
Rhenium (186Re) obisbemeda by Plus Therapeutics for Head And Neck Cancer: Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Head And Neck Cancer....
Rhenium (186Re) obisbemeda by Plus Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC)....
Rhenium (186Re) obisbemeda by Plus Therapeutics for Squamous Cell Carcinoma: Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Squamous Cell Carcinoma. According...
Rhenium (186Re) obisbemeda by Plus Therapeutics for Kaposi Sarcoma: Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Kaposi Sarcoma. According to...
Rhenium (186Re) obisbemeda by Plus Therapeutics for Lung Adenocarcinoma: Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Lung Adenocarcinoma. According to...
Rhenium (186Re) obisbemeda by Plus Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM)....
Rhenium (186Re) obisbemeda by Plus Therapeutics for Head And Neck Cancer: Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Head And Neck Cancer....